lorigerlimab

Phase 2

MacroGenics, Inc. (MGNX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jul '27

MGNXPhase 2$263M

Lorigerlimab Phase 2 Est. Readout

lorigerlimab• Androgen-Independent Prostatic Cancer80

Jul 2027~ConfirmedSTALE

CT.gov

00%

Feb '27

MGNXPhase 2$263M

Lorigerlimab Phase 2 Est. Readout

lorigerlimab• Androgen-Independent Prostatic Cancer60

Feb 2027~ConfirmedSTALE

CT.gov

00%

Development History

Sep '26

MGNXPhase 2$263M

lorigerlimab Phase 2 Est. Readout

lorigerlimab• Androgen-Independent Prostatic Cancer154

Sep 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Androgen-Independent Prostatic Cancer

View Full Landscape

Drug Information

Target Indication

Androgen-Independent Prostatic Cancer

Clinical Trial

NCT05848011

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MGNX

MacroGenics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

TeplizumabPhase 3

Type 1 Diabetes Mellitus

MargetuximabPhase 3

HER-2 Positive Breast Cancer

RetifanlimabPhase 3

Gastric Cancer

Margetuximab 10 mg/kgPhase 2

Gastric Cancer

vobramitamab duocarmazine 2.0 mg (Arm A)Phase 2

Castration-Resistant Prostatic Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts